HOME >> MEDICINE >> NEWS
Long-term benefits found in two drugs for Parkinson's

Two drugs used to treat hallucinations in patients with Parkinsons disease (PD) can not only reduce hallucinations, but may also lead to long-term benefits in these patients, according to a group of Emory University researchers. The long-term benefits may include reduced mortality and a reduced risk of nursing home placement. The drugs studied were the atypical antipsychotics quetiapine (trade name Seroquel) and clozapine (trade name Clozaril).

Jorge Juncos, M.D., associate professor of neurology, Emory University School of Medicine, and colleagues will present their findings at the American Academy of Neurology 54th Annual Meeting in Denver, Colo., on April 18. The research will also appear as an abstract in the April issue of the journal, Neurology.

"Drug-induced psychotic symptoms, such as visual hallucinations, are seen in a significant number of patients with advanced PD," says Dr. Juncos. "Approximately 15 to 20 percent of PD patients may experience these hallucinations over time. They are due to a interaction between the progression of the illness and the drugs used to treat its symptoms," Dr. Juncos explains.

The Emory researchers conducted a retrospective chart review between 1996 and 2001 in 27 patients with advanced PD (mean duration of illness of 13 years, plus or minus six years). Hallucinations had been treated for approximately 36 months using quetiapine in 23 patients and clozapine in four patients.

"We compared the antipsychotic efficacy, mortality and risk of nursing home placement to published historical data (Goetz & Stebbins, Neurology 1996) in similarly affected patients treated with low doses of typical anti-psychotics before 1996," Dr. Juncos says.

Based on clinical exams or caregiver reports, Emory researchers found hallucinations in these patients were reduced by almost half (from 100 to 59 percent) while patients were on one of the study medications. Symptoms of agitation were also re
'"/>

Contact: Janet Christenbury
jmchris@emory.edu
404-727-8599
Emory University Health Sciences Center
18-Apr-2002


Page: 1 2

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
3. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
4. Long-term obesity linked to loss of brain tissue in women
5. Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
6. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
7. Long-term use of antibiotics possibly linked with increased risk of breast cancer
8. Long-term follow-up of mortality in patients with community-acquired pneumonia
9. Long-term outcome of epilepsy surgery is favorable for many
10. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
11. Long-term avoidance of milk in children results in poor bone health

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Long term benefits found two drugs for Parkinson

(Date:6/19/2013)... 19, 2013 PrettySkin4Less announces it is ... serums by top skin care manufacturer EMINENCE to ... of vitamins, minerals and active organic ingredients to promote ... many other beauty products offer. For this reason it’s ... , "I like products that do what they ...
(Date:6/19/2013)... 2013 Kleritec, Inc. announced the addition ... http://www.kleritec.com . In the recent expansion Kleritec ... activities packages for pre-school and day care providers. The ... to aid teachers across the United States the ability ... , Included in the art and activities packages is ...
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... 19, 2013 The Journal of Parasitology ... today’s computer software, it creates questions of ethics. For ... As an already published case shows, scientific publications need ... The Journal of Parasitology features a ... a 2004 article published in the Journal of the ...
(Date:6/19/2013)... online edition of the journal Nature , a ... California, San Diego School of Medicine visually monitored the ... occurs in zebrafish after cardiac ventricular injury. Their ... heart are more plastic, or capable of transformation into ... the research reveals a novel potential source of cells ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:Kleritec Announces Addition of Educational Products. 2Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2
(Date:6/19/2013)... BURLINGTON, Mass. , June 19, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... the majority of surveyed U.S. and European rheumatologists ... of the attributes that most influences their prescribing ... U.S. and European rheumatologists, respectively, rank the percentage ...
(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a segment ... ), a leading global medical technology company, today announced the ... the latest in its line of high-performance research flow cytometers. ... high-performance multicolor analysis with the most compact footprint in its ... and a height of 30" (76.2 cm). Recognizing that space ...
(Date:6/19/2013)... PRINCETON, N.J. , June 19, 2013 ... Belrose Pharma, a new specialty pharmaceutical company ... generation of innovative injectable and sustained release ... high unmet medical needs, today announced the ... (Customized Linker Technology®) platform and associated product ...
Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
Cached News: